Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kendra N Avery

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Scientific Reports|January 16, 2015
Development of a high affinity, non-covalent biologic to add functionality to FabsKendra N Avery, Cindy Zer, Krzysztof P Bzymek, et al.
Acta Crystallographica. Section F, Structural Biology Communications|December 5, 2017
Meditope-Fab interaction: threading the holeKrzysztof P Bzymek, Yuelong Ma, Kendra N Avery, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 9, 2013
Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodiesJoshua M Donaldson, Cindy Zer, Kendra N Avery, et al.
Protein Engineering, Design & Selection : PEDS|April 22, 2017
Engineering a high-affinity peptide binding site into the anti-CEA mAb M5ACindy Zer, Kendra N Avery, Kassondra Meyer, et al.
Nature Communications|April 22, 2018
Mechanically interlocked functionalization of monoclonal antibodiesKrzysztof P Bzymek, James W Puckett, Cindy Zer, et al.
Frontiers in Medicine|May 4, 2023
Using quantitative single molecule localization microscopy to optimize multivalent HER2-targeting ligandsDevin L Wakefield, Ottavia Golfetto, Raphael Jorand, et al.
Journal of the American Chemical Society|September 27, 2018
A Platform To Enhance Quantitative Single Molecule Localization MicroscopyOttavia Golfetto, Devin L Wakefield, Eliedonna E Cacao, et al.
Molecular Cancer Therapeutics|September 20, 2024
A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager ImmunotherapiesGregory L Moore, Veronica G Zeng, Juan E Diaz, et al.
Frontiers in Pharmacology|June 18, 2024
Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapyRajbharan Yadav, Suzanne Schubbert, Patrick G Holder, et al.
Nature Communications|January 15, 2015
Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cellsCan Küçük, Bei Jiang, Xiaozhou Hu, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Scientific Reports|January 16, 2015
Development of a high affinity, non-covalent biologic to add functionality to FabsKendra N Avery, Cindy Zer, Krzysztof P Bzymek, et al.
Acta Crystallographica. Section F, Structural Biology Communications|December 5, 2017
Meditope-Fab interaction: threading the holeKrzysztof P Bzymek, Yuelong Ma, Kendra N Avery, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 9, 2013
Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodiesJoshua M Donaldson, Cindy Zer, Kendra N Avery, et al.
Protein Engineering, Design & Selection : PEDS|April 22, 2017
Engineering a high-affinity peptide binding site into the anti-CEA mAb M5ACindy Zer, Kendra N Avery, Kassondra Meyer, et al.
Nature Communications|April 22, 2018
Mechanically interlocked functionalization of monoclonal antibodiesKrzysztof P Bzymek, James W Puckett, Cindy Zer, et al.
Frontiers in Medicine|May 4, 2023
Using quantitative single molecule localization microscopy to optimize multivalent HER2-targeting ligandsDevin L Wakefield, Ottavia Golfetto, Raphael Jorand, et al.
Journal of the American Chemical Society|September 27, 2018
A Platform To Enhance Quantitative Single Molecule Localization MicroscopyOttavia Golfetto, Devin L Wakefield, Eliedonna E Cacao, et al.
Molecular Cancer Therapeutics|September 20, 2024
A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager ImmunotherapiesGregory L Moore, Veronica G Zeng, Juan E Diaz, et al.
Frontiers in Pharmacology|June 18, 2024
Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapyRajbharan Yadav, Suzanne Schubbert, Patrick G Holder, et al.
Nature Communications|January 15, 2015
Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cellsCan Küçük, Bei Jiang, Xiaozhou Hu, et al.
Pageof 1